ARTICLE | Company News
Savant HWP, National Institutes of Health neurology, endocrine/metabolic news
January 14, 2013 8:00 AM UTC
Savant HWP received a $6.5 million grant from the NIH's National Institute on Drug Abuse (NIDA) to develop Savant's 18-methoxycoronaridine (18-MC) to treat drug addiction, obesity and other forms of compulsive behavior. 18-MC is a small molecule that selectively antagonizes the nicotinic acetylcholine receptor alpha(3)beta(4), a subtype of the nicotinic receptor that indirectly activates the dopaminergic mesolimbic system. The company will use the grant to support IND-enabling studies and GMP scale-up. ...